Skip to content

Released May 8, 2025, after the close

10-Q filed May 8, 2025, 38 days after period end · 0001410578-25-001112

Q1 2025 · 10-Q
Revenue$2.34M+92.0% vs Q1 2024−41.9% vs Q4 2024
Net Income-$10.72MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted$0.36+33.3% vs Q1 2024no prior Q4 2024 on file
Gross Profit$1,853,000+114.0%
Operating Income-$11,166,000N/M
Operating Cash Flow-$8,283,000N/M
Margins · derived
Gross margin79.2%+8.1 pt vs Q1 2024
Operating margin-477.0%+169.2 pt vs Q1 2024
Net margin-458.1%+82.1 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024
Revenue$2.34M$1.22M
Net Income-$10.72M-$6.59M
EPS Diluted$0.36$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR